Cheng Yuan-Yuan, Peng Rui-Rui, Luo Hao, Zhao Wei
Clinical Center for Sexually Transmitted Disease, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Postepy Dermatol Alergol. 2024 Feb;41(1):66-71. doi: 10.5114/ada.2023.135613. Epub 2024 Feb 28.
Melasma is an acquired hypermelanosis and occurs in areas exposed to sunlight.
To investigate the effectiveness of Danggui Shaoyao powder (DSP) as a complementary drug in the treatment of melasma.
A total of 40 melasma patients over the age of 18 who met the inclusion criteria entered the study randomly in two DSP + Hydroquinone (DSP + H) and Hydroquinone (H) groups.
At the beginning of the study, the average MASI score of the two groups of patients had no statistical difference (DSP + H: 15.79 ±1.01 vs. H: 15.37 ±1.17, = 0.23). But from the eighth week of treatment, the MASI score of the patients decreased significantly and in the DSP + H group it decreased statistically significantly compared to the H group (DSP + H: 5.83 ±0.97 vs. H: 8.29 ±2.23, < 0.001 for the eighth week and DSP + H: 3.60 ±0.58 vs. H: 5.52 ±1.73, < 0.001 for the twelfth week of the treatment). It means after 12 weeks of treatment, the average MASI score of patients in the DSP + H group decreased by 77.26 ±2.70%, but in the grroup H, it decreased by 64.31 ±9.68% ( < 0.001). Dynamic PGA showed that excellent treatment occurred in 65% of the + H group H, but only 20% of the H group ( = 0.01).
Oral DSP for 12 weeks along with hydroquinone cream can significantly reduce the MASI score of melasma patients and increase the patients' recovery and satisfaction.
黄褐斑是一种后天性色素沉着过度疾病,发生于暴露于阳光下的部位。
探讨当归芍药散(DSP)作为辅助药物治疗黄褐斑的有效性。
共有40例年龄在18岁以上符合纳入标准的黄褐斑患者,随机分为DSP + 氢醌(DSP + H)组和氢醌(H)组。
研究开始时,两组患者的平均MASI评分无统计学差异(DSP + H组:15.79 ±1.01 vs. H组:15.37 ±1.17,P = 0.23)。但从治疗第8周起,患者的MASI评分显著下降,且DSP + H组与H组相比差异有统计学意义(治疗第8周时,DSP + H组:5.83 ±0.97 vs. H组:8.29 ±2.23,P < 0.001;治疗第12周时,DSP + H组:3.60 ±0.58 vs. H组:5.52 ±1.73,P < 0.001)。这意味着治疗12周后,DSP + H组患者的平均MASI评分下降了77.26 ±2.70%,而H组下降了64.31 ±9.68%(P < 0.001)。动态医师整体评估(PGA)显示,DSP + H组65%的患者治疗效果极佳,而H组仅为20%(P = 0.01)。
口服DSP 12周联合氢醌乳膏可显著降低黄褐斑患者的MASI评分,提高患者的治愈率和满意度。